Cashed-up Insmed keeps eye on market ball as Arikace strategy laid out
This article was originally published in Scrip
Executive Summary
Insmed recently grossed $25.7 million from a direct public offering of common stock, building on the company's $73.1 million cash and investment balance as of 30 June, while keeping its clinical studies on track for the antibiotic Arikace (inhaled liposomal amikacin) after clinical holds on US trials for the orphan lung disease treatment were lifted earlier this year.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).